drugset / Trial / NCT02103998

Study of Thyroid Hormones in Prematures

NCT02103998

RandomizedSingle-groupTriple-blindTreatment

Summary

The investigators hypothesize that continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days from birth will reduce by 30% or more (from an estimated 30% to 21%) the proportion of extremely low gestational age subjects with a composite endpoint of "cerebral palsy (CP) or a Bayley III Composite Cognitive Score \< 85" at 36 months corrected postnatal age (CA).

Timeline

Start
2020-07-01
Primary completion
2025-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levothyroxine Other / unclassified 4 ug/kg
Subject potassium iodide Unknown 30 ug/kg Oral